Enanta Pharmaceuticals, Inc.

NasdaqGS ENTA

Enanta Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 58.23 M

Enanta Pharmaceuticals, Inc. Net Cash Used For Investing Activities is USD 58.23 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 208.69% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Enanta Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -53.58 M, a -197.60% change year over year.
Enanta Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 54.90 M, a 48.41% change year over year.
Enanta Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 36.99 M, a 86.54% change year over year.
Enanta Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 19.83 M, a 122.88% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: ENTA

Enanta Pharmaceuticals, Inc.

CEO	Dr. Jay R. Luly Ph.D.
IPO Date	March 21, 2013
Location	United States
Headquarters	500 Arsenal Street
Employees	145
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years